Looking forward to exploring opportunities and meeting you in person at CPHI Middle East, Riyadh, from 10-12 December! Visit us at Stand # 2.D22. To meet our local #Procurement and #Business #Development teams, schedule a time via the CPHI booking system: https://lnkd.in/dnfRM4rk Know more about Hikma - https://lnkd.in/dGsGpV2K #Hikma #CPHI #Innovation #Healthcare #Pharmaceuticals #MENA #Investors #Biopharma #Manufacturing #CMO
Hikma Pharmaceuticals
制药业
London，London 518,098 位关注者
At Hikma, we help put better health, within reach, every day.
关于我们
For 45 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 760* high-quality generic, speciality and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 30 manufacturing plants, 9 R&D centres and c9,100 employees worldwide. *As of February 2024 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
- 网站
-
https://www.hikma.com
Hikma Pharmaceuticals的外部链接
- 所属行业
- 制药业
- 规模
- 5,001-10,000 人
- 总部
- London，London
- 类型
- 上市公司
- 创立
- 1978
- 领域
- Oral Generics、Injectables、Generics、Manufacturing、Medicines、Healthcare、Pharmaceuticals、Nasal、Contract Manufacturing、Sterile generic injectables、Branded generics、In-licensed patented products和Non-injectable generic and specialty products
地点
-
主要
获取路线
1 New Burlington Place
GB，London，London，W1S 2HR
Hikma Pharmaceuticals员工
动态
-
#News for #Investors and #Media. Listen to our CEO, Riad Mishlawi and CFO, Khalid Nabilsi, at the #JefferiesHealthcare Conference on Wednesday 20 November 2024, 15:00 – 15:25 GMT Tune in here https://lnkd.in/dc4ckyNs They will discuss Hikma's strategic progress and our strong positioning for growth, driven by our three business segments Injectables, Branded, and Generics. Learn more: https://lnkd.in/e3wVpu2k
-
-
#News for #Investors and #Media. Access Hikma’s recording and transcript from the visit to our Casablanca facilities by investors and sell-side analysts. Our leadership team provided insights into our unique position and growth opportunities across the MENA region. This hands-on experience highlighted Hikma's commitment to innovation and excellence as we expand our portfolio and reach. Listen to the recording: https://lnkd.in/guEtBFPq View transcript here: https://lnkd.in/g7FQwSDk #Hikma #Pharmaceuticals #MENA #Innovation
-
-
On #WorldDiabetesDay, Hikma acknowledges the increasing prevalence of diabetes globally and its significant impact on people wellbeing. In the Middle East and North Africa (MENA), the number of adults with diabetes is projected to rise to 136 million by 2045, an increase of 87% [1]. As part of our commitment, we continue to provide innovative solutions in the MENA region to assist patients in managing their health effectively. #Hikma for a better #DiabetesLife For more go to: www.hikma.com 1. https://lnkd.in/eFRXuBYP
-
-
#News for #Investors and #Media Today, our sell-side analysts and investors are touring our Casablanca, Morocco manufacturing site. They will meet with the Hikma MENA leadership team, visit our high-quality plants, and learn about our positioning and growth prospects in the MENA region. Hikma has grown to become the second-largest pharmaceutical company by sales in the MENA region [1] by building a broad portfolio, including treatments for chronic illnesses, addressing high unmet healthcare needs. Our Moroccan site, acquired over ten years ago, manufactures general formulations and penicillin. We are expanding with a new sterile injectable plant in Morocco, the first to localise certain high-demand injectable medicines. The plant is set to be operational in 2025. #Hikma #Pharmaceuticals #MENA #Growth Read presentation here: https://lnkd.in/gDXrFaC8 Learn about our business in the MENA region: https://lnkd.in/g7YhwiyV [1] IQVIA MIDAS Pharma Index MAT Jul-2024. Data includes Retail and Hospital Sales Excluding Milks and diagnostics
Hikma Pharmaceuticals in the Middle East and North Africa
https://www.youtube.com/
-
Over 90% of critical medicines in the EU are #generics, which are crucial for millions of lives and healthcare systems. ?? We need a #CriticalMedicinesAct NOW to secure access to life-saving treatments. Let’s make support for essential medicines a top priority! ?? #EUCriticalHealth
-
-
This #GlobalBiosimilarsWeek2024, we recognise the role of biosimilars in providing patients with affordable access to essential medicines in #MENA, and our role in these efforts. Through our deep understanding of the MENA #healthcare landscape, our strategic partnerships, and by collaborating with healthcare professionals, together we are broadening access to care to offer more #innovative #treatment options for patients. Read more: https://lnkd.in/dpKin3tn #Innovation #PatientCare
-
-
This World Quality Week, we recognise the essential role that quality plays at Hikma and celebrate keeping our high standards at the forefront of everything we do. Our collective commitment to quality is not just about compliance, but it is what allows us to continue to put better health within reach, every day, driving patient safety, and improving healthcare outcomes for communities around the world. Hear from our Executive Committee members about why quality is meaningful to them. For more: www.hikma.com #WorldQualityWeek2024 #Hikma
-
Meet Nawras Bny Yassien (NEBOSH - TecIOSH - ISO Lead Auditor), Health, Safety, and Environment, Manager for Hikma Chemical and Hikma Jordan and discover why he likes working at #Hikma! Watch the video. https://lnkd.in/dR9jy3mM Learn more https://lnkd.in/eZn8C9TV
#OwnYourCareer | Nawras A. BnyYassien , Health, Safety, and Environment, Manager for HC and HJ
https://www.youtube.com/
-
Today, #Hikma provides an update on current trading and confirms continued strong strategic execution while reiterating its guidance. Riad Mishlawi, Hikma’s CEO, said: “I am pleased with our progress this year and we remain on track to deliver another strong performance in 2024, in line with our current guidance. All three businesses are contributing, with new launches across our markets and investment in our infrastructure giving us confidence for the future. We have made excellent strategic progress in the period, having closed the Xellia acquisition and signed an important contract manufacturing agreement for our Generics business.” Read press release here https://lnkd.in/g4hvnHSY #TradingUpdate #Financials #Guidance
-